Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951278805> ?p ?o ?g. }
- W2951278805 endingPage "4213" @default.
- W2951278805 startingPage "4200" @default.
- W2951278805 abstract "Background Compared with single-drug TACE, our previous phase III study demonstrated that triple-drug transarterial chemoembolization (TACE) prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). The aim of this study was to find which patients can benefit from the triple drugs TACE compared with single-drug TACE. Methods Patients in the triple-drug TACE arm received sponge embolization and emulsions composed of 50 mg epirubicin, 50 mg lobaplatin, 6 mg mitomycin C, and lipiodol, while patients in the single-drug TACE arm received sponge embolization and emulsions composed of 50 mg epirubicin and lipiodol. From July 2007 to November 2009, 244 patients (224 men and 20 women; age ranged from 21 to 75 years) from our phase III study formed the initial cohort. From January 2010 to June 2015, external validation cohort was composed of 449 patients (411 men and 38 women; age ranged from 18 to 75 years) from another institution. The validation cohort after propensity score matching (PSM) (n = 374) was analyzed. Cox proportional hazard model was used to evaluate the interaction term between treatments for each subgroup. This retrospective study was approved by the institutional review board at each center. Results No difference was observed in the baseline characteristic of three cohorts. This exploratory analysis showed that triple-drug TACE brought a survival benefit in the initial cohort, validation cohort (before PSM), and validation cohort (after PSM) compared with single-drug TACE. The outcomes of three cohorts all showed that a significantly greater OS triple-drug chemotherapy benefit versus single-drug chemotherapy was seen in patients with large tumors (larger than 10 cm) while no survival difference was seen in patients with small tumors (10 cm or smaller). Conclusions Triple-drug TACE seems to benefit patients with HCC larger than 10 cm in particular compared with single-drug TACE." @default.
- W2951278805 created "2019-06-27" @default.
- W2951278805 creator A5003799076 @default.
- W2951278805 creator A5010353388 @default.
- W2951278805 creator A5017755691 @default.
- W2951278805 creator A5020613063 @default.
- W2951278805 creator A5027920102 @default.
- W2951278805 creator A5045788528 @default.
- W2951278805 creator A5059473032 @default.
- W2951278805 creator A5059888014 @default.
- W2951278805 creator A5060402791 @default.
- W2951278805 creator A5073318338 @default.
- W2951278805 creator A5077866420 @default.
- W2951278805 creator A5087378677 @default.
- W2951278805 date "2019-06-17" @default.
- W2951278805 modified "2023-10-13" @default.
- W2951278805 title "Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma" @default.
- W2951278805 cites W1964895069 @default.
- W2951278805 cites W1968534394 @default.
- W2951278805 cites W1970184322 @default.
- W2951278805 cites W2012394155 @default.
- W2951278805 cites W2020803311 @default.
- W2951278805 cites W2027733391 @default.
- W2951278805 cites W2032224733 @default.
- W2951278805 cites W2034267111 @default.
- W2951278805 cites W2038997022 @default.
- W2951278805 cites W2040216663 @default.
- W2951278805 cites W2042209473 @default.
- W2951278805 cites W2043490217 @default.
- W2951278805 cites W2050344385 @default.
- W2951278805 cites W2057378223 @default.
- W2951278805 cites W2061703796 @default.
- W2951278805 cites W2064604565 @default.
- W2951278805 cites W2091304504 @default.
- W2951278805 cites W2092950906 @default.
- W2951278805 cites W2113864541 @default.
- W2951278805 cites W2125763116 @default.
- W2951278805 cites W2128067825 @default.
- W2951278805 cites W2135506385 @default.
- W2951278805 cites W2137794033 @default.
- W2951278805 cites W2146775265 @default.
- W2951278805 cites W2155163959 @default.
- W2951278805 cites W2157744213 @default.
- W2951278805 cites W2163403599 @default.
- W2951278805 cites W2168776543 @default.
- W2951278805 cites W2234453634 @default.
- W2951278805 cites W2271921187 @default.
- W2951278805 cites W2319748653 @default.
- W2951278805 cites W2322115081 @default.
- W2951278805 cites W2528185757 @default.
- W2951278805 cites W2766398846 @default.
- W2951278805 cites W2810306141 @default.
- W2951278805 cites W2902109874 @default.
- W2951278805 cites W4245784696 @default.
- W2951278805 doi "https://doi.org/10.1002/cam4.2355" @default.
- W2951278805 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6675716" @default.
- W2951278805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31207163" @default.
- W2951278805 hasPublicationYear "2019" @default.
- W2951278805 type Work @default.
- W2951278805 sameAs 2951278805 @default.
- W2951278805 citedByCount "7" @default.
- W2951278805 countsByYear W29512788052020 @default.
- W2951278805 countsByYear W29512788052021 @default.
- W2951278805 countsByYear W29512788052022 @default.
- W2951278805 countsByYear W29512788052023 @default.
- W2951278805 crossrefType "journal-article" @default.
- W2951278805 hasAuthorship W2951278805A5003799076 @default.
- W2951278805 hasAuthorship W2951278805A5010353388 @default.
- W2951278805 hasAuthorship W2951278805A5017755691 @default.
- W2951278805 hasAuthorship W2951278805A5020613063 @default.
- W2951278805 hasAuthorship W2951278805A5027920102 @default.
- W2951278805 hasAuthorship W2951278805A5045788528 @default.
- W2951278805 hasAuthorship W2951278805A5059473032 @default.
- W2951278805 hasAuthorship W2951278805A5059888014 @default.
- W2951278805 hasAuthorship W2951278805A5060402791 @default.
- W2951278805 hasAuthorship W2951278805A5073318338 @default.
- W2951278805 hasAuthorship W2951278805A5077866420 @default.
- W2951278805 hasAuthorship W2951278805A5087378677 @default.
- W2951278805 hasBestOaLocation W29512788051 @default.
- W2951278805 hasConcept C121608353 @default.
- W2951278805 hasConcept C126322002 @default.
- W2951278805 hasConcept C141071460 @default.
- W2951278805 hasConcept C143998085 @default.
- W2951278805 hasConcept C167135981 @default.
- W2951278805 hasConcept C207103383 @default.
- W2951278805 hasConcept C2778019345 @default.
- W2951278805 hasConcept C2778448856 @default.
- W2951278805 hasConcept C2780835546 @default.
- W2951278805 hasConcept C44249647 @default.
- W2951278805 hasConcept C50382708 @default.
- W2951278805 hasConcept C530470458 @default.
- W2951278805 hasConcept C71924100 @default.
- W2951278805 hasConcept C72563966 @default.
- W2951278805 hasConcept C90924648 @default.
- W2951278805 hasConceptScore W2951278805C121608353 @default.
- W2951278805 hasConceptScore W2951278805C126322002 @default.
- W2951278805 hasConceptScore W2951278805C141071460 @default.
- W2951278805 hasConceptScore W2951278805C143998085 @default.